Nonalcoholic Steatohepatitis: A Search for Factual Animal Models

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Sanches, Sheila Cristina L ^a   Ramalho, Leandra Naira Z ^a   Augusto, Marlei Josiele ^a   Da Silva, Deisy Mara ^a   Ramalho, Fernando Silva ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; FRUCTOSE; METHIONINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ANIMAL MODEL; CHOLESTEROL DIET; DB/DB MOUSE; GENETIC MODEL; HIGH FRUCTOSE DIET; LIPID DIET; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OB/OB MOUSE; RABBIT MODEL; REVIEW; RODENT MODEL; TRANSGENIC MOUSE; ZUCKER RAT; ANIMAL; DISEASE COURSE; DISEASE MODEL; GENETICS; HUMAN; LIVER CIRRHOSIS; MOUSE; PATHOPHYSIOLOGY; RAT;

ANIMALIA; MUS; RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LIVER CIRRHOSIS; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS;

EID: 84929629712     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/574832     Document Type: Review

References (73)

1. M. Basaranoglu, S. Kayacetin, N. Yilmaz, E. Kayacetin, O. Tarcin, and A. Sonsuz, "Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease," World Journal of Gastroenterology, vol. 16, no. 18, pp. 2223-2226, 2010.
2. E. Bugianesi, "Review article: steatosis, the metabolic syndrome and cancer," Alimentary Pharmacology and Therapeutics, Supplement, vol. 22, no. 2, pp. 40-43, 2005.
3. V. L. Misra, M. Khashab, and N. Chalasani, "Nonalcoholic fatty liver disease and cardiovascular risk," Current Gastroenterology Reports, vol. 11, no. 1, pp. 50-55, 2009.
4. E. M. Brunt, D. E. Kleiner, C. Behling et al., "Misuse of scoring systems," Hepatology, vol. 54, no. 1, pp. 369-370, 2011.
5. A. Wieckowska and A. E. Feldstein, "Diagnosis of nonalcoholic fatty liver disease: Invasive versus noninvasive," Seminars in Liver Disease, vol. 28, no. 4, pp. 386-395, 2008.
6. J. K. Dyson, Q. M. Anstee, and S. McPherson, "Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging,"Frontline Gastroenterology, vol. 5, no. 3, pp. 211-218, 2014.
7. P. Bedossa, C. Poitou, N. Veyrie et al., "Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients," Hepatology, vol. 56, no. 5, pp. 1751-1759, 2012.
8. P. Angulo, "Nonalcoholic fatty liver disease," The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
9. K. Mehta, D. H. van Thiel, N. Shah, and S. Mobarhan, "Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants," Nutrition Reviews, vol. 60, no. 9, pp. 289-293, 2002.
10. A. P. Rolo, J. S. Teodoro, and C. M. Palmeira, "Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis," Free Radical Biology & Medicine, vol. 52, no. 1, pp. 59-69, 2012.
11. A. Rashid, T.-C. Wu, C.-C. Huang et al., "Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver," Hepatology, vol. 29, no. 4, pp. 1131-1138, 1999.
12. R. P. Witek, W. C. Stone, F. G. Karaca et al., "Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis," Hepatology, vol. 50, no. 5, pp. 1421-1430, 2009.
13. G. C. Farrell, C. Z. Larter, J. Y. Hou et al., "Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression," Journal of Gastroenterology and Hepatology, vol. 24, no. 3, pp. 443-452, 2009.
14. A. E. Feldstein, A. Canbay, P. Angulo et al., "Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis," Gastroenterology, vol. 125, no. 2, pp. 437-443, 2003.
15. P. S. Ribeiro, H. Cortez-Pinto, S. Solá et al., "Hepatocyte apoptosis, expression of death receptors, and activation of NF-κB in the liver of nonalcoholic and alcoholic steatohepatitis patients," American Journal of Gastroenterology, vol. 99, no. 9, pp. 1708-1717, 2004.
16. R. M. Ramalho, H. Cortez-Pinto, R. E. Castro et al., "Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis,"European Journal of Gastroenterology and Hepatology, vol. 18, no. 1, pp. 21-29, 2006.
17. M. V. MacHado and H. Cortez-Pinto, "Cell death and nonalcoholic steatohepatitis: where is ballooning relevant?" Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 213-222, 2011.
18. T. Luedde, N. Kaplowitz, and R. F. Schwabe, "Cell death and cell death responses in liver disease: mechanisms and clinical relevance," Gastroenterology, vol. 147, no. 4, pp. 765-783, 2014.
19. W. Peverill, L. W. Powell, and R. Skoien, "Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation,"International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8591-8638, 2014.
20. Q. Cheng, N. Li, M. Chen et al., "Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats,"Digestive Diseases and Sciences, vol. 58, no. 10, pp. 2895-2902, 2013.
21. S. Thapaliya, A. Wree, D. Povero et al., "Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model," Digestive Diseases and Sciences, vol. 59, no. 6, pp. 1197-1206, 2014.
22. M. Rizzo, G. Montalto, and M. Vinciguerra, "Exploring lipid-related treatment options for the treatment of NASH," Current Vascular Pharmacology, vol. 12, no. 5, pp. 741-744, 2014.
23. B. A. Neuschwander-Tetri, "Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites," Hepatology, vol. 52, no. 2, pp. 774-788, 2010.
24. N. Anderson and J. Borlak, "Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis," Pharmacological Reviews, vol. 60, no. 3, pp. 311-357, 2008.
25. L. Hebbard and J. George, "Animal models of nonalcoholic fatty liver disease," Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 1, pp. 34-44, 2011.
26. O. Kucera and Z. Cervinkova, "Experimental models of nonalcoholic fatty liver disease in rats," World Journal of Gastroenterology, vol. 20, no. 26, pp. 8364-8376, 2014.
27. I. Shimomura, R. E. Hammer, J. A. Richardson et al., "Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy," Genes & Development, vol. 12, no. 20, pp. 3182-3194, 1998.
28. M. S. Strable and J. M. Ntambi, "Genetic control of de novo lipogenesis: role in diet-induced obesity," Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 3, pp. 199-214, 2010.
29. H. Nakayama, S. Otabe, T. Ueno et al., "Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis," Metabolism: Clinical and Experimental, vol. 56, no. 4, pp. 470-475, 2007.
30. Y. Takahashi, Y. Soejima, and T. Fukusato, "Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis,"World Journal of Gastroenterology, vol. 18, no. 19, pp. 2300-2308, 2012.
31. R. S. Ahima and J. S. Flier, "Leptin," Annual Review of Physiology, vol. 62, pp. 413-437, 2000.
32. Q. M. Anstee and R. D. Goldin, "Mouse models in non-alcoholic fatty liver disease and steatohepatitis research," International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1-16, 2006.
33. A. Qamar, S. Z. Sheikh, A. Masud et al., "In vitro and in vivo protection of stellate cells from apoptosis by leptin," Digestive Diseases and Sciences, vol. 51, no. 10, pp. 1697-1705, 2006.
34. A. M. Diehl, "Lessons from animal models of NASH," Hepatology Research, vol. 33, no. 2, pp. 138-144, 2005.
35. A. E. Brix, A. Elgavish, T. R. Nagy, B. A. Gower, W. J. Rhead, and P. A. Wood, "Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse," Molecular Genetics and Metabolism, vol. 75, no. 3, pp. 219-226, 2002.
36. M. Wortham, L. He, M. Gyamfi, B. L. Copple, and Y.-J. Y. Wan, "The transition from fatty liver to NASH associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet," Digestive Diseases and Sciences, vol. 53, no. 10, pp. 2761-2774, 2008.
37. A. Sahai, P. Malladi, X. Pan et al., "Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin,"The American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 287, no. 5, pp. G1035-G1043, 2004.
38. L. Fellmann, A. R. Nascimento, E. Tibiriça, and P. Bousquet, "Murine models for pharmacological studies of the metabolic syndrome," Pharmacology & Therapeutics, vol. 137, no. 3, pp. 331-340, 2013.
39. V. Vendramini, A. P. Cedenho, S. M. Miraglia, and D. M. Spaine, "Reproductive function of the male obese Zucker rats: alteration in sperm production and sperm DNA damage," Reproductive Sciences, vol. 21, no. 2, pp. 221-229, 2014.
40. M. Carmiel-Haggai, A. I. Cederbaum, and N. Nieto, "A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats," The FASEB Journal, vol. 19, no. 1, pp. 136-138, 2005.
41. S. C. Grubb, G. A. Churchill, and M. A. Bogue, "A collaborative database of inbred mouse strain characteristics," Bioinformatics, vol. 20, no. 16, pp. 2857-2859, 2004.
42. J. Yu, E. Ip, A. Dela Peña et al., "COX-2 induction in mice with experimental nutritional steatohepatitis: role as proinflammatory mediator," Hepatology, vol. 43, no. 4, pp. 826-836, 2006.
43. R. S. McCuskey, Y. Ito, G. R. Robertson, M. K. McCuskey, M. Perry, and G. C. Farrell, "Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice," Hepatology, vol. 40, no. 2, pp. 386-393, 2004.
44. J. George, N. Pera, N. Phung, I. Leclercq, J. Y. Hou, and G. Farrell, "Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis," Journal of Hepatology, vol. 39, no. 5, pp. 756-764, 2003.
45. C. Z. Larter, M. M. Yeh, J. Williams, K. S. Bell-Anderson, and G. C. Farrell, "MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes," Journal of Hepatology, vol. 49, no. 3, pp. 407-416, 2008.
46. A. Ferramosca and V. Zara, "Modulation of hepatic steatosis by dietary fatty acids," World Journal of Gastroenterology, vol. 20, no. 7, pp. 1746-1755, 2014.
47. C. S. Lieber, M. A. Leo, K. M. Mak et al., "Model of nonalcoholic steatohepatitis," The American Journal of Clinical Nutrition, vol. 79, no. 3, pp. 502-509, 2004.
48. Z.-J. Xu, J.-G. Fan, X.-D. Ding, L. Qiao, and G.-L. Wang, "Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats," Digestive Diseases and Sciences, vol. 55, no. 4, pp. 931-940, 2010.
49. P. Starkel and I. A. Leclercq, "Animal models for the study of hepatic fibrosis," Best Practice and Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 319-333, 2011.
50. Q.-G. Deng, H. She, J. H. Cheng et al., "Steatohepatitis induced by intragastric overfeeding in mice," Hepatology, vol. 42, no. 4, pp. 905-914, 2005.
51. Y. Zou, J. Li, C. Lu et al., "High-fat emulsion-induced rat model of nonalcoholic steatohepatitis," Life Sciences, vol. 79, no. 11, pp. 1100-1107, 2006.
52. F. R. Jornayvaz, V. T. Samuel, and G. I. Shulman, "The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome," Annual Review of Nutrition, vol. 30, pp. 273-290, 2010.
53. J. K. Kim, M. D. Michael, S. F. Previs et al., "Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle," Journal of Clinical Investigation, vol. 105, no. 12, pp. 1791-1797, 2000.
54. M. Marí, F. Caballero, A. Colell et al., "Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis,"Cell Metabolism, vol. 4, no. 3, pp. 185-198, 2006.
55. N. Matsuzawa, T. Takamura, S. Kurita et al., "Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet," Hepatology, vol. 46, no. 5, pp. 1392-1403, 2007.
56. B. P. Sampey, A. M. Vanhoose, H. M. Winfield et al., "Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose inflammation: comparison to high-fat diet,"Obesity, vol. 19, no. 6, pp. 1109-1117, 2011.
57. J. F. Lalanza, A. Caimari, J. M. Del Bas et al., "Effects of a post-weaning cafeteria diet in young rats: metabolic syndrome, reduced activity and low anxiety-like behaviour," PLoS ONE, vol. 9, no. 1, Article ID e85049, 2014.
58. J. Carillon, C. Romain, G. Bardy et al., "Cafeteria diet induces obesity and insulin resistance associated with oxidative stress but not with inflammation: improvement by dietary supplementation with a melon superoxide dismutase," Free Radical Biology and Medicine, vol. 65, pp. 254-261, 2013.
59. M. Pasarín, V. La Mura, J. Gracia-Sancho et al., "Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD," PLoS ONE, vol. 7, no. 4, Article ID e32785, 2012.
60. X. Ouyang, P. Cirillo, Y. Sautin et al., "Fructose consumption as a risk factor for non-alcoholic fatty liver disease," Journal of Hepatology, vol. 48, no. 6, pp. 993-999, 2008.
61. M. F. Abdelmalek, A. Suzuki, C. Guy et al., "Increased fructose consumptionisassociatedwithfibrosisseverityinpatientswith nonalcoholic fatty liver disease," Hepatology, vol. 51, no. 6, pp. 1961-1971, 2010.
62. F. R. Jornayvaz, M. J. Jurczak, H.-Y. Lee et al., "A highfat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain," The American Journal of Physiology - Endocrinology and Metabolism, vol. 299, no. 5, pp. E808-E815, 2010.
63. T. Ishimoto, M. A. Lanaspa, C. J. Rivard et al., "High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase," Hepatology, vol. 58, no. 5, pp. 1632-1643, 2013.
64. Z. Khitan and D. H. Kim, "Fructose: a key factor in the development of metabolic syndrome and hypertension," Journal of Nutrition and Metabolism, vol. 2013, Article ID 682673, 12 pages, 2013.
65. A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S. C. Bischoff, and I. Bergheim, "Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice,"Hepatology, vol. 50, no. 4, pp. 1094-1104, 2009.
66. J. S. Lim, M. Mietus-Snyder, A. Valente, J.-M. Schwarz, and R. H. Lustig, "The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome," Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 5, pp. 251-264, 2010.
67. L. H. Tetri, M. Basaranoglu, E. M. Brunt, L. M. Yerian, and B. A. Neuschwander-Tetri, "Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent," The American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 295, no. 5, pp. G987-G995, 2008.
68. R. Kohli, M. Kirby, S. A. Xanthakos et al., "High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis," Hepatology, vol. 52, no. 3, pp. 934-944, 2010.
69. M. Ganz, T. Csak, and G. Szabo, "High fat diet feeding results in gender specific steatohepatitis and inflammasome activation,"World Journal of Gastroenterology, vol. 20, no. 26, pp. 8525-8534, 2014.
70. M. Charlton, A. Krishnan, K. Viker et al., "Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition," The American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 301, no. 5, pp. G825-G834, 2011.
71. J.-F. Fu, Y.-L. Fang, L. Liang, C.-L. Wang, F. Hong, and G.-P. Dong,"Arabbitmodelofpediatricnonalcoholicsteatohepatitis: the role of adiponectin," World Journal of Gastroenterology, vol. 15, no. 8, pp. 912-918, 2009.
72. T. Ogawa, H. Fujii, K. Yoshizato, and N. Kawada, "A humantype nonalcoholic steatohepatitis model with advanced fibrosis in rabbits," The American Journal of Pathology, vol. 177, no. 1, pp. 153-165, 2010.
73. K. Otogawa, K. Kinoshita, H. Fujii et al., "Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis," The American Journal of Pathology, vol. 170, no. 3, pp. 967-980, 2007.